Carbachol Can Be Released at a Cholinergic Ganglionic Synapse As a False Transmitter (Acetylcholine/Acetylcholinesterase/Quantal Release/Intracellular Injection) G

Total Page:16

File Type:pdf, Size:1020Kb

Carbachol Can Be Released at a Cholinergic Ganglionic Synapse As a False Transmitter (Acetylcholine/Acetylcholinesterase/Quantal Release/Intracellular Injection) G Proc. NatL Acad. Sci. USA Vol. 80, pp. 5126-5128, August 1983 Neurobiology Carbachol can be released at a cholinergic ganglionic synapse as a false transmitter (acetylcholine/acetylcholinesterase/quantal release/intracellular injection) G. BAUX AND L. TAUC Laboratoire de Neurobiologie cellulaire, Centre National de la Recherche Scientifique, 91190 Gif-sur-Yvette, France Communicated by S. Hagiwara, May 3, 1983 ABSTRACT Carbachol was injected into a presynaptic cho- itory Cl--dependent postsynaptic responses in a nearby group linergic neuron in the buccal ganglion of Aplysia and the quantal of neurons (6). The pre- and postsynaptic cells were each pen- aspects of the ClP-dependent postsynaptic response to a pro- etrated by two separate low-resistance 3 M KCI-filled elec- longed stimulation were analyzed by a statistical fluctuation method. trodes (1-5 MW). The calculated amplitude of the miniature postsynaptic current Transmission was studied by using a method described by was increased with respect to control. Statistical fluctuation anal- Simonneau et aL (7). Both pre- and postsynaptic cells were si- ysis was also used to analyze the postsynaptic response obtained during ionophoretic application of acetylcholine and carbachol. multaneously voltage clamped to holding potentials of -50 mV The calculated unitary channel current was found to be greater and -80 mV, respectively. In the presence of TTX (0.1 mM), for carbachol than for acetylcholine. This increase could explain a 3-s step depolarization of the presynaptic neuron induced a the larger miniature postsynaptic current seen after intracellular postsynaptic response (LDIPSC, long depolarization-induced injection of carbachol into the presynaptic neuron if carbachol postsynaptic current), which showed fluctuations or "noise. " was released at the synapse as a false transmitter. This conclusion The amplitude of the miniature postsynaptic currents (MPSC) was supported by the observation that it was possible to restore was calculated by using Campbell's theorem, in which the size transmission at a synapse previously blocked by presynaptic in- of the unitary element or individual MPSC (i) is related to the tracellular injection of acetylcholinesterase with a presynaptic in- variance of the noise (E2) and the mean observed current change jection of carbachol. (I) by the equation: i = 2E2/I (8). Agonists were ionophoretically applied to the cell body of The specificity of the synaptic release mechanism is not ab- the postsynaptic neuron bearing AcCho receptors (9). The same solute and substances with molecular formulae relatively close equation was used to calculate the current crossing a single to the natural transmitter can be liberated. At cholinergic syn- channel opened by AcCho or carbachol, with the omission of apses, precursors like homocholine, monoethylcholine, and the factor 2, because of the pulse-like aspect of the elementary triethylcholine are taken up by cholinergic nerve terminals, current (8, 10). In all experiments, the null potential (-40 to acetylated, and released as false transmitters. This property has -55 mV) of the postsynaptic responses was continuously mon- been used as a tool to understand the mechanism of transmitter itored and the currents were expressed as conductance. release (1-4). A Fourier transform was used to calculate the power density We have investigated whether the well-known acetylcholine spectra from which the decay time constant of the MPSC and (AcCho) analogue, carbachol (carbamoylcholine chloride) can the channel open time were estimated (7). As previously shown, be released at a cholinergic synapse. Carbachol has the inter- the MPSC spectra could be approximated by single Lorentzian esting property of not being hydrolyzed by acetylcholinesterase curves (7), whereas spectra of Cl- channel noise could only be (AcChoE) and as such can be used as a pharmacological tool in fitted by double Lorentzians (11, 12). Thus, it may be hazard- the presence of large quantities of this enzyme. Carbachol is ous to give absolute values of the channel open time; the values not taken up by cholinergic terminals and having no acetyl group, reported here are indicative and concern only the slower com- it cannot be synthesized in the cytoplasm. We have overcome ponent. this difficulty by injecting carbachol into a presynaptic cholin- AcCho and carbachol were intracellularly injected by ion- ergic neuron of Aplysia buccal ganglion. We have found that it tophoresis with a constant current. Postsynaptic current re- can act as a false transmitter and can also replace AcCho at a sponses used for calculation and presented in the figures were synapse previously blocked by intracellular injection of Ac- obtained with 3-s depolarizations of the presynaptic neuron to ChoE (5). 0 mV. However, the difference in the actions of AcCho and car- bachol shown below was observed for other levels of presyn- MATERIALS AND METHODS aptic depolarization. AcChoE (Worthington) was injected as a 5% solution (wt/vol) Experiments were performed at room temperature (20-22°C) by an air pressure system on the buccal ganglion of Aplysia californica obtained from R. (5). Fay (Pacific Biomarine, Venice, CA). The ganglion was dis- sected free of connective tissue and perfused with artificial sea RESULTS water (460 mM NaCl/10 mM KCl/11 mM CaCJ2/25 mM MgCl2/ Fig. 1 illustrates the postsynaptic responses obtained when either 28 mM MgSO4/10 mM Tris-HC1, pH 7.8). Tetrodotoxin (TTX) AcCho or carbachol was injected into the presynaptic neuron. (Sigma) at 0.1 mM was added to block Na+ channels. Cells used After a delay, both drugs increase the amplitude of the mean were two cholinergic interneurons, which each induce inhib- postsynaptic current, and this increase is related to the amount The publication costs of this article were defrayed in part by page charge Abbreviations: AcCho, acetylcholine; AcChoE, acetylcholinesterase; TTX, payment. This article must therefore be hereby marked "advertise- tetrodotoxin; LDIPSC, long depolarization-induced postsynaptic cur- ment" in accordance with 18 U.S.C. §1734 solely to indicate this fact. rent; MPSC, miniature postsynaptic currents. 5126 Downloaded by guest on September 27, 2021 Neurobiology: Baux and Taue Proc. Natl. Acad. Sci. USA 80 (1983) 5127 A B to the enzymatic action of AcChoE (11). On the other hand, AcCho-activated channels may be differently affected by AcCho and carbachol. When AcCho and carbachol were ionophoresed at the same spot on the postsynaptic cell by using a double-bar- reled electrode, we found that the single channel conductances calculated for the (inhibitory) responses having the same mean current were different (Fig. 2). The mean (±SD) values ob- served in 15 experiments were 3.4 ± 0.8 pS for AcCho and 5.2 ± 1.1 pS for carbachol. In contrast, the calculated mean open time of the slower component of the Cl- channel was some- what shorter (by about 25%) with carbachol (10 ± 2 ms) than with AcCho (14 ± 2 ms). To ascertain that the difference in conductance of inhibitory channels activated by AcCho and carbachol was not an ex- -J perimental artefact, we used the same channel analysis in other Aplysia cells having excitatory receptors opening cation-selec- tive "sodium" channels (13). We found that these channels, whether opened by AcCho or carbachol, have essentially the same amplitudes but a shorter lifetime with carbachol, as al- ready shown by others (13). It should be mentioned that mean FIG. 1. Postsynaptic current response after sustained depolariza- single channel conductances and lifetimes computed from in- tions of the presynaptic neuron to 0 mV. Upper traces, DC recordings; lower traces, AC recordings at higher gain of the current fluctuations tegrated spectral densities for current fluctuations in frog end (calibrations, 4 nA for DC and 1 nA for AC recordings; time, 1 s). (A) plates were dependent on the agonists used (14). 1, test response; 2, response after a 30-min injection of carbachol with Another possible mechanism responsible for the increase in 50-nA constant current; 3, after another 30-min injection of carbachol. MPSC amplitude after carbachol injection could reside in a fa- The calculated amplitude of the MPSC was 1.09 nS in 1, 1.54 nS in 2, cilitatory action of a "leakage" or a nonquantal release of car- and 1.95 nS in 3. (B) In another preparation similar to the experiment bachol, shifting the sigmoid amplitude/concentration curve of inA, but AcCho was injected instead ofcarbachol. The amplitude ofthe MPSC remained unchanged (0.5 nS) throughout. The increase in am- released AcCho to the right (15). To test this possibility, we ana- plitude of the LDIPSC after AcCho injections is due exclusively to an lyzed the LDIPSC of noninjected preparations in the presence increase in the number of quanta released, whereas injected carbachol of carbachol (1 tkM to 0.1 mM) in the perfusing medium. In no increases both the quantal content and the size of MPSC. case was an increase in MPSC amplitude calculated. Thus, the larger unit conductance induced by carbachol on of the drug introduced into the presynaptic cell. Because in- the postsynaptic membrane explains the increase in amplitude tracellular ionophoresis increases the intracellular concentra- of the MPSC calculated after injection of carbachol into the tion of the drugs progressively, it is impossible to quantify the presynaptic neuron. After the injection of carbachol, each delay. Also, the final intracellular concentration reached after quantum released probably consists of a mixture of AcCho and injection cannot be precisely calculated, as the transfer number carbachol. The proportion of carbachol increases with the of the injection electrode is not known. It can be estimated as quantity of carbachol injected. being on the order of millimolar. The injected neuron showed The other method we used to show release of carbachol from a decrease in membrane potential, and when voltage clamped, the presynaptic neuron takes advantage of the fact that release the outward, presumably late K current was slightly decreased of AcCho is abolished by injection of AcChoE into the pre- during the depolarizing pulse.
Recommended publications
  • Proprietary Name Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22-562 PROPRIETARY NAME REVIEW(S) Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Date: February 24, 2010 Donna Griebel, MD To: Director, Division of Gastroenterology Products Denise Toyer, Pharm.D., Deputy Director Through: Carol Holquist, R.Ph., Director Division of Medication Error Prevention and Analysis Zachary Oleszczuk, PharmD, Acting Team Leader From: Division of Medication Error Prevention and Analysis Subject: Proprietary Name Review Carbaglu (Carglumic Acid) Tablets Drug Name(s): 200 mg Application Type/Number: NDA 022562 Applicant: Orphan Europe, SARL OSE RCM #: 2009-2140 CONTENTS 1 INTRODUCTION......................................................................................................................................... 3 2 METHODS.................................................................................................................................................... 3 3 RESULTS...................................................................................................................................................... 3 4 CONCLUSIONS AND RECOMMENDATIONS........................................................................................ 3 5 REFERENCES.............................................................................................................................................. 3 2 1 INTRODUCTION This
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’
    0270.6474/85/0505-1202$02.00/O The Journal of Neuroscience CopyrIght 0 Society for Neuroscrence Vol. 5, No. 5, pp. 1202-1207 Printed in U.S.A. May 1985 Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’ EDWIN M. MEYER* AND DEBORAH H. OTERO Department of Pharmacology and Therapeutics, University of Florida School of Medicine, Gainesville, Florida 32610 Abstract brain (Gonzales and Crews, 1984). M,-receptors, however, appear pre- and postsynaptically in brain, are regulated by an intrinsic The muscarinic receptors that modulate acetylcholine membrane protein that binds to GTP (g-protein), and may not be release from rat cortical synaptosomes were characterized coupled to changes in phosphatidylinositol turnover. with respect to sensitivity to drugs that act selectively at M, The present studies were designed to determine whether M,- or or Ma receptor subtypes, as well as to changes in ionic Mp-receptors mediate the presynaptic modulation of ACh release. strength and membrane potential. The modulatory receptors These studies involve dose-response curves for the release of appear to be of the M2 type, since they are activated by synaptosomal [3H]ACh in the presence of selected muscarinic ago- carbachol, acetylcholine, methacholine, oxotremorine, and nists and antagonists, as well as treatments that selectively alter MI- bethanechol, but not by pilocarpine, and are blocked by or M,-receptor activity. Our results indicate that the presynaptic atropine, scopolamine, and gallamine (at high concentra- modulation of [3H]ACh release is mediated by MP- but not MI- tions), but not by pirenzepine or dicyclomine.
    [Show full text]
  • Pharmacology of Ophthalmologically Important Drugs James L
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.
    [Show full text]
  • The Use of Central Nervous System Active Drugs During Pregnancy
    Pharmaceuticals 2013, 6, 1221-1286; doi:10.3390/ph6101221 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Use of Central Nervous System Active Drugs During Pregnancy Bengt Källén 1,*, Natalia Borg 2 and Margareta Reis 3 1 Tornblad Institute, Lund University, Biskopsgatan 7, Lund SE-223 62, Sweden 2 Department of Statistics, Monitoring and Analyses, National Board of Health and Welfare, Stockholm SE-106 30, Sweden; E-Mail: [email protected] 3 Department of Medical and Health Sciences, Clinical Pharmacology, Linköping University, Linköping SE-581 85, Sweden; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +46-46-222-7536, Fax: +46-46-222-4226. Received: 1 July 2013; in revised form: 10 September 2013 / Accepted: 25 September 2013 / Published: 10 October 2013 Abstract: CNS-active drugs are used relatively often during pregnancy. Use during early pregnancy may increase the risk of a congenital malformation; use during the later part of pregnancy may be associated with preterm birth, intrauterine growth disturbances and neonatal morbidity. There is also a possibility that drug exposure can affect brain development with long-term neuropsychological harm as a result. This paper summarizes the literature on such drugs used during pregnancy: opioids, anticonvulsants, drugs used for Parkinson’s disease, neuroleptics, sedatives and hypnotics, antidepressants, psychostimulants, and some other CNS-active drugs. In addition to an overview of the literature, data from the Swedish Medical Birth Register (1996–2011) are presented. The exposure data are either based on midwife interviews towards the end of the first trimester or on linkage with a prescribed drug register.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Drugs/Medications Known to Cause Diaphoresis
    Drugs/Medications Known to Cause Diaphoresis Certain prescription and non-prescription medications can cause diaphoresis (excess perspiration or sweating) as a side effect. A list of potentially sweat-inducing medications is provided below. Medications are listed alphabetically by generic name. U.S. brand names are given in parentheses, if applicable. This list is provided as a resource and a service. It is not exhaustive and is in no way meant to replace consultation with a medical professional. Although sweating is a known side effect of the medications listed below, in most cases only a small percentage of people using the medicines experience undue sweating (in some cases less than 1%). Medications noted with an “*” are the most likely to cause sweating and the frequency of sweating as a side effect from these medications may be as high as 50%. Abciximab (ReoPro®) Acamprosate (Campral®) Acetaminophen and Tramadol (Ultracet™) Acetophenazine (NA) Acetylcholine (Miochol-E®) Acetylcysteine (Acetadote®) Acitretin (Soriatane®) Acrivastine and Pseudoephedrine (Semprex®-D) Acyclovir (Zovirax®) Adenosine (Adenocard®; Adenoscan®) Alemtuzumab (Campath®) Almotriptan (Axert™) Alosetron (Lotronex®) Ambenonium (Mytelase®) Amitriptyline (Elavil®) Amlodipine (Norvasc®) Amoxapine (NA) Amphotericin B (Liposomal) (AmBisome®) Anastrozole (Arimidex®) Anidulafungin (Eraxis™) Antihemophilic Factor (Recombinant) (Advate; Helixate® FS; Kogenate® FS; Recombinate™; ReFacto®) Antithymocyte Globulin (Equine) (Atgam®) Antithymocyte Globulin (Rabbit) (Thymoglobulin®)
    [Show full text]
  • Drugs Which Can Affect Near Vision: a Useful List
    Drugs Which Can Affect Near Vision: A Useful List Joanne L. Smith B.Sc., Ph.Phm.* J. Raymond Buncic, M.D., F.R.C.S.(C)t ABSTRACT This paper documents a list of drugs that cause problems with near vision, by virtue of effects on accommodation, occasionally refractive error and diplopia. It is meant as a reference aid to the clinician when confronted with problems of focusing on near objects or print. There are many drugs that have been reported to interfere with near or reading vision, producing blurring, decreased accommodation and diplopia. This paper lists the drugs that have been reported in the literature to produce symptoms which interfere with near vision. Case reports for the listed drugs vary greatly from many to few. The drugs have been divided into the following categories: those causing (A) blurring at near, (B) diplopia and (C) induced myopia. Those drugs which only rarely cause these symptoms have been omitted. From the Departments of Pharmacy* and Ophthalmologyt, The Hospital For Sick Children, Toronto, Ontario, Canada Requests for reprints should be addressed to: Dr. J. Raymond Buncic, Department of Ophthalmology, The Hospital For Sick Children, 555 University Ave., Toronto, Ontario, Canada M5G lX8 TABLE 1 DRUGS COMMONLY CAUSING DIFFICULTY WITH FOCUSING AT NEAR OR BLURRED VISION. DRUG INCIDENCE REFERENCE Antipsychotics Chlorpromazine 14-23 8 Clozapine 5 8,14 Fluphenazine 1.2-4.3 8 Haloperidol 6.8-16 8 Loxapine 12,14 Perphenazine 7.4-17.8 8 Pimozide 20 8 Risperidone 1-2%, >/= 10% 11 Thioridazine 0.6-18 8 Thiothixene 20 8
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]